Medisyn Technologies is a valued research partner committed to providing biotech partners and research collaborators with scientific support in bioactive compound and extract development projects in the areas of pharmaceutical, nutraceutical, animal health, and agrichemical via development agreements, strategic alliances and long-term partnerships.

Medisyn is able to assist companies of all sizes with their needs - from novel drug and bioactive ingredient screening to lead optimization to de novo design.

A few of our valued customers:

Research and licensing collaboration with Kraft Foods Global Inc. to discover effective bioactive ingredients suitable for food use.
 

 Small Business Innovation Research (SBIR) Phase I grant from the Department of Defense (DoD) to discover and develop new non-steroidal anti-inflammatory drugs (NSAIDs) with reduced gastrointestinal toxicity. 

 

Collaboration for the development of novel β-amyloid (Aβ) lowering drugs as a treatment in Alzheimer’s disease. In vitro evidence substantiates that Medisyn's technology was successful in building a predictive model for Aβ-lowering activity. Validated and characterized lead compounds will be out-licensed to pharmaceutical companies for further clinical development. Commercialization rights will be shared between MSSM and Medisyn Technologies. 
 

       

   

 

 

Discovery collaboration for the development of small molecules targeting inflammatory and neurological diseases. The collaboration is based on the discovery technology platforms available at each company and will serve to develop pre-clinically validated lead compounds within joint and airway inflammations as well as Multiple Sclerosis, pain relief and Parkinson’s Disease. 

Multi-year strategic alliance to accelerate the discovery and development of natural, non-prescription compounds focused on disease prevention. 

 

        

 

 

  

 

Collaborative research agreement Invitrogen’s Drug Discovery Solutions group extends an earlier working relationship between the two companies. This collaboration builds upon a previously successful evaluation with Invitrogen’s GibcoTM subsidiary in which Medisyn’s predictive technology was applied to the areas of cell culture media improvement. The results discovered in the GibcoTM project were nonobvious and indicated that Medisyn’s technology could be practically applied to specialty media development. This latest research agreement called for the use of Medisyn’s molecular topology-based Fast Forward EngineeringTM platform to optimize chemical modulators of kinase function.